Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, including Parkinson’s disease, Rett syndrome, and Fragile X.
GOOGL is consolidating near $176 with technical indicators pointing to a potential breakout above $177.4. The 20 EMA aligns with the $175 support level, reinforcing the consolidation zone and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results